SCHEMBL4867095

SCHEMBL4867095

CC(NC(=O)N1CCCCc2ccccc21)c1ccc(F)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.53
GRM7 Q14831 1/20 0.53
LMNA P02545 3/20 0.51
POLB P06746 3/20 0.51
MAPT P10636 2/20 0.51
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
ALDH1A1 P00352 3/20 0.49
RAB9A P51151 1/20 0.49
PDE4B Q07343 1/20 0.48
PDE4D Q08499 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
NOTUM Q6P988 1/20 0.48
PRMT5 O14744 1/20 0.47
WDR77 Q9BQA1 1/20 0.47
HTT P42858 1/20 0.47
TSHR P16473 1/20 0.47
RECQL P46063 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MAPK1 P28482 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4866021 0.89 POLB (0.57) THRBGRM7LMNAPOLBMAPT
SCHEMBL4866008 0.89 POLB (0.57) THRBGRM7LMNAPOLBMAPT
SCHEMBL4868227 0.84 POLB (0.60) THRBGRM7LMNAPOLBMAPT
SCHEMBL4870684 0.79 MAPT (0.67) THRBLMNAPOLBMAPTMEN1
SCHEMBL31077935 0.79 HTT (0.56) GRM7MAPTALDH1A1RAB9ANOTUM
SCHEMBL4866912 0.79 AVPR2 (0.56) THRBLMNAPOLBMAPTMEN1
SCHEMBL4870873 0.78 POLB (0.61) THRBLMNAPOLBMAPTMEN1
SCHEMBL4867148 0.78 POLB (0.48) THRBLMNAPOLBMAPTMEN1
SCHEMBL4867654 0.78 POLB (0.48) THRBLMNAPOLBMAPTMEN1
SCHEMBL4869441 0.77 TP53 (0.61) THRBLMNAMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368444-B2 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-05-06 US claimed
US-7368444-B2 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-05-06 US disclosed
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 US disclosed
EP-1475368-A1 N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-11-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient CNR1, CNR2, NPSR1 THRB 1930/4885GRM7 234/4885LMNA 2162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.